ANN ARBOR, MI — November 4, 2025 — Leads & Copy — Zomedica Corp. (OTCQB:ZOMDF) reported record year-over-year revenue for the 19th straight quarter, with third-quarter revenue up 16% to $8.1 million.
The animal health company’s growth was fueled by strong demand for PulseVet® and Assisi® therapeutic devices, accelerated adoption of diagnostic products like the TRUFORMA® platform, and the introduction of a new Development Services revenue stream. Development Services revenue, related to human health sector opportunities, was $0.7M for the quarter.
Consumable revenues grew 14% to $5.4 million, and gross margin was 67%. Total operating expenses decreased by $0.5 million, and the net loss decreased by 9% to $6.1 million.
Zomedica had $54.4 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2025.
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
Source: Zomedica Corp.
